Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has announced the approval of a capital raising initiative through the issuance of options to investors. The announcement, dated December 29, 2023, detailed the approval by shareholders for the issuance of 1,371,428,571 unlisted Short Dated Options and 457,142,857 Long Dated Options, with exercise prices of A$0.007 and A$0.01 respectively. The Short Dated Options will expire on August 31, 2024, while the Long Dated Options, which are proposed to be listed subject to ASX requirements, will expire on August 31, 2026. The options are attached to fully paid ordinary shares under a placement approved at the general meeting on December 29, 2023. The offer is available to invitees determined by the company and closes on January 5, 2024. The announcement also included the resignation of CFO Kathryn Andrews and the appointment of Phillip Hains as the new CFO effective January 31, 2024.
Alterity Therapeutics Limited, a development stage enterprise, has announced the approval of a capital raising initiative through the issuance of options to investors. The announcement, dated December 29, 2023, detailed the approval by shareholders for the issuance of 1,371,428,571 unlisted Short Dated Options and 457,142,857 Long Dated Options, with exercise prices of A$0.007 and A$0.01 respectively. The Short Dated Options will expire on August 31, 2024, while the Long Dated Options, which are proposed to be listed subject to ASX requirements, will expire on August 31, 2026. The options are attached to fully paid ordinary shares under a placement approved at the general meeting on December 29, 2023. The offer is available to invitees determined by the company and closes on January 5, 2024. The announcement also included the resignation of CFO Kathryn Andrews and the appointment of Phillip Hains as the new CFO effective January 31, 2024.
处于发展阶段的企业Alterity Therapeutics Limited宣布通过向投资者发行期权来批准一项筹资计划。该公告于2023年12月29日发布，详细说明了股东批准发行1,371,428,571份非上市短期期权和457,142,857份远期期权，行使价分别为0.007澳元和0.01澳元。短期期权将于2024年8月31日到期，而拟按澳大利亚证券交易所要求上市的远期期权将于2026年8月31日到期。根据2023年12月29日股东大会批准的配售，这些期权附于已全额支付的普通股。该优惠适用于公司确定的受邀者，将于2024年1月5日结束。该公告还包括首席财务官凯瑟琳·安德鲁斯的辞职以及任命菲利普·海恩斯为新任首席财务官，自2024年1月31日起生效。
处于发展阶段的企业Alterity Therapeutics Limited宣布通过向投资者发行期权来批准一项筹资计划。该公告于2023年12月29日发布，详细说明了股东批准发行1,371,428,571份非上市短期期权和457,142,857份远期期权，行使价分别为0.007澳元和0.01澳元。短期期权将于2024年8月31日到期，而拟按澳大利亚证券交易所要求上市的远期期权将于2026年8月31日到期。根据2023年12月29日股东大会批准的配售，这些期权附于已全额支付的普通股。该优惠适用于公司确定的受邀者，将于2024年1月5日结束。该公告还包括首席财务官凯瑟琳·安德鲁斯的辞职以及任命菲利普·海恩斯为新任首席财务官，自2024年1月31日起生效。
有用
没用